Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prempro WHI Implications For Future HRT Trials To Be Discussed By Subcmte.

Executive Summary

Implications of the Women's Health Initiative study results for future clinical trials of hormone replacement therapy will be discussed by an ad hoc subcommittee of FDA's Reproductive Health Drugs Advisory Committee on Nov. 12-13
Advertisement

Related Content

FDA Women’s Health Initiative Advisory Committee Meeting Postponed
FDA Women’s Health Initiative Advisory Committee Meeting Postponed
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
FDA Reproductive Cmte. Membership Reflects “Broken Process” – Crawford
Prempro, Premarin Not Indicated For Coronary Heart Disease – Revised Label
Prempro, Premarin Not Indicated For Coronary Heart Disease – Revised Label
Advertisement
UsernamePublicRestriction

Register

PS040629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel